Showing results (61-70 of 83) with videos related to
Sort By:
Pageof 9
British Journal of Haematology|August 4, 2017
Transformed Waldenström macroglobulinaemia: clinical presentation and outcome. A multi-institutional retrospective study of 77 cases from the French Innovative Leukemia Organization (FILO)Eric Durot, Cécile Tomowiak, Anne-Sophie Michallet, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 20, 2016
Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II TrialRalf U Trappe, Daan Dierickx, Heiner Zimmermann, et al.Transplantation|May 15, 2018
Immunosuppression Is Associated With Clinical Features and Relapse Risk of B Cell Posttransplant Lymphoproliferative Disorder: A Retrospective Analysis Based on the Prospective, International, Multicenter PTLD-1 TrialsHeiner Zimmermann, Nina Babel, Daan Dierickx, et al.Blood|December 22, 2021
Obinutuzumab plus lenalidomide in advanced, previously untreated follicular lymphoma in need of systemic therapy: a LYSA studyEmmanuel Bachy, Roch Houot, Pierre Feugier, et al.Blood|March 17, 2011
Autologous stem cell transplantation as a first-line treatment strategy for chronic lymphocytic leukemia: a multicenter, randomized, controlled trial from the SFGM-TC and GFLLCLaurent Sutton, Sylvie Chevret, Olivier Tournilhac, et al.The Lancet. Haematology|December 25, 2017
Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 studyCaroline Dartigeas, Eric Van Den Neste, Julie Léger, et al.Leukemia & Lymphoma|July 4, 2015
Evaluating abbreviated induction with fludarabine, cyclophosphamide, and dose-dense rituximab in elderly patients with chronic lymphocytic leukemiaCaroline Dartigeas, Eric Van Den Neste, Christian Berthou, et al.Blood|February 18, 2021
BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemiaCharles Herbaux, Christoph Kornauth, Stéphanie Poulain, et al.Acta Clinica Belgica|February 23, 2017
Results from the Belgian mantle cell lymphoma registryVibeke Vergote, Ann Janssens, Marc André, et al.The New England Journal of Medicine|September 28, 2017
Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell LymphomaSteven Le Gouill, Catherine Thieblemont, Lucie Oberic, et al.Pageof 9